不良事件报告系统
医学
不利影响
梅德林
药理学
化学
生物化学
作者
Jinger Lin,X.Y. Chen,Min Luo,Qianwei Zhuo,Haosong Zhang,Nuo Chen,Yunqian Zhuo,Yue Han
标识
DOI:10.3389/fphar.2024.1420478
摘要
Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI